Successfully completed 6 inspections by European Regulatory Agencies.

24 USFDA Inspections successfully completed

Lotus Labs has successfully completed 3^rd inspection by MHRA, UK.

Lotus Labs has successfully completed inspection by National Pharmaceutical Regulatory Agency (NPRA), Malaysia.

Lotus Labs supported the new initiative of Generics bulletin to recognize the tremendous work done by executives in the global generics and biosimilars industries by being part of the event and sponsoring an award. The event was held at Paris on October 7th 2014 during CPHI Worldwide.
Based on company submissions and nominations, the top three entries for the company of the year award were AMCo, Hikma and Julphar pharma.
In creating the Global Generics & Biosimilars Awards 2014, Lotus Labs sponsored the Award - Company of the year - EMEA and announced Hikma Pharmaceuticals as the winner of the sponsored category. The award recognizes excellent performance across a range of business activities and was won in strong competition against a number of leading EMEA pharmaceutical companies. 
More than 150 invited guests – including several CEOs and other senior managers – from the industries’ leading players gathered to network and celebrate at an evening Awards ceremony.
Mr. Hari Sankar, Managing Director- Lotus Labs seen below announcing the winner and presenting the award to the Hikma representative.

Lotus Labs has received its renewed ANVISA permission on 24th Oct 2014 for all the four facilities, which is valid till 24th Oct 2015 for the conduct of clinical, analytical, statistical and bioavailability studies.

Lotus has successfully completed its 16th USFDA inspection in October 2014 increasing the total number of audits faced till date to 62.

Lotus Labs has got its CAP (College of American Pathologists) accreditation renewed till year 2016.

Lotus has successfully completed USFDA audit in September 2013

Bioequivalence studies performed at Lotus Labs from the period of October 2013 to October 2015 would be received by BPFK

Lotus has successfully completed WHO audit in April 2013 increasing the total number of audits faced till date to 58

Lotus has successfully completed MHRA audit in October 2012 and ANVISA audit in December 2012

Lotus has actively participated in CPHI 2012 @ Madrid and AAPS 2012 @ Chicago. Please find the attached photographs for the same

Lotus has successfully completed the process of Self Identification Number with FDA. Please append the attached word document for DUNS numbers.

Lotus Labs has been recognized as an approved Bioequivalence Evaluation Centre by National Pharmaceutical Control Bureau ( BPFK), Ministry of Heath, Malaysia.

Bioequivalence studies performed in Lotus Labs from the period of May 2010 to May 2013 would be received by BPFK.

 Lotus Labs has been recognized as one of the “Best Enterprises” in the field of Clinical Research, India, by the European Business Assembly ,Socrates Committee, Oxford ,UK, 2012.